<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04554615</url>
  </required_header>
  <id_info>
    <org_study_id>Postoperative hyperglycemia</org_study_id>
    <nct_id>NCT04554615</nct_id>
  </id_info>
  <brief_title>Intensive Insulin Therapy as Therapeutic Strategy for Non-diabetic Hyperglycemia After Surgery in ICU</brief_title>
  <official_title>Intensive Insulin Therapy as Therapeutic Strategy for Non-diabetic Hyperglycemia After Surgery in ICU</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study hypothesizes that the use of Intravenous intensive insulin therapy (IV-IIT)&#xD;
      may be beneficial than IV conventional insulin therapy (IV-CIT) for improving the outcome of&#xD;
      non-diabetic surgical patients had postoperative (PO) stress hyperglycemia (PSH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All postoperative patients who will be admitted to surgical ICU and develop (PSH) will be&#xD;
      eligible for evaluation for inclusion and exclusion criteria.&#xD;
&#xD;
      Prior to initiation of IV-IT (insulin therapy), blood samples will be obtained to estimate&#xD;
      base-line Blood Glucose level (BG). BG will be estimated hourly during IV-IT to guard against&#xD;
      development of hypoglycemic episodes. The assigned IV-IT will continue till reaching the&#xD;
      target BG for each group and then will be stopped and patients will be shifted to&#xD;
      subcutaneous (sc)-IT. During maintenance sc-IT, BG level will be estimated 6-hourly to assure&#xD;
      maintenance of BG within the desired range, otherwise if hyperglycemia recurred or its&#xD;
      induced complications as hyperglycemic ketoacidosis or hyperosmolar coma or infectious&#xD;
      complications developed, IV-IT will be resumed and BG will be followed-up hourly. The same&#xD;
      sequence of follow-up will be continued till stability of BG at the targeted level. IV-IT&#xD;
      will be provided as following :&#xD;
&#xD;
      Conventional insulin therapy (CIT) will be provided as a continuous infusion of 50 IU of&#xD;
      Actrapid HM in 50 ml of 0.9% sodium chloride using a pump. Infusion will be adjusted to&#xD;
      achieve BG level in range of 180-200 mg/dl.&#xD;
&#xD;
      Intensive insulin therapy (IIT) will be provided as an insulin infusion at rate of 1&#xD;
      mU/kg/min and will be adjusted to achieve target BG level in range of 80-110 mg/dl.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Actual">June 10, 2018</completion_date>
  <primary_completion_date type="Actual">March 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of IV-Insulin Therapy sessions required till stabilization of the targeted Blood Glucose level.</measure>
    <time_frame>180 days</time_frame>
    <description>insulin infusion will be given in shots to control the high blood sugar and the times of giving these shots will be counted</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration to control hyperglycemia</measure>
    <time_frame>180 days</time_frame>
    <description>the duration till stabilization of the targeted BG level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day ICU morbidity</measure>
    <time_frame>180 days</time_frame>
    <description>hyperglycemic hyperosmolar coma, diabetic ketoacidosis and infections will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 - day ICU mortality</measure>
    <time_frame>180 days</time_frame>
    <description>patients died within 28 days of ICU admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Postoperative Complications</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Conventional Insulin Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CIT was provided as a continuous infusion of 50 IU of Actrapid HM in 50 ml of 0.9% sodium chloride using a pump, Infusion was adjusted to achieve BG level in range of 180-200 mg/dl.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Insulin Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IIT was provided as an insulin infu-sion at rate of 1 mU/kg/min and was adjusted to achieve target BG level in range of 80-110 mg/dl.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>insulin infusion to control postoperative hyperglycemia</description>
    <arm_group_label>Conventional Insulin Therapy</arm_group_label>
    <arm_group_label>Intensive Insulin Therapy</arm_group_label>
    <other_name>Blood sugar measurement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All postoperative patients who will be admitted to surgical ICU and developed Post&#xD;
             Surgical Hyperglycemia will be eligible for evaluation for inclusion and exclusion&#xD;
             criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All patients having diabetes mellitus, history of preoperative stress hyperglycemia,&#xD;
             endocrinopathies, obesity defined as body mass index (BMI) &gt;30 kg/m2, age younger than&#xD;
             18 years, renal impairment or maintenance on renal replacement therapy and liver&#xD;
             diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Abosamak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Security Forces Hospital</name>
      <address>
        <city>Riyadh</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>March 7, 2021</last_update_submitted>
  <last_update_submitted_qc>March 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>MOHAMMED FAWZI ALI ABOSAMAK</investigator_full_name>
    <investigator_title>Clinical professor of anesthesia and critical care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Once approved by clinical trial.gov data will be participated</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

